Search results for "Phase III as Topic"

showing 10 items of 41 documents

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

2020

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. Methods and findings We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-…

Apolipoprotein BPublication Ethics030204 cardiovascular system & hematologyCardiovascularGastroenterologyLipoprotein particleMedical and Health SciencesBiochemistrychemistry.chemical_compoundDatabase and Informatics Methods0302 clinical medicineMathematical and Statistical TechniquesAnticholesteremic Agents Apolipoproteins B Cholesterol Cholesterol LDL Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Dicarboxylic Acids Fatty Acids Humans Hypercholesterolemia Peptide Fragments Randomized Controlled Trials as TopicLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert PanelMedicine and Health SciencesDicarboxylic Acids030212 general & internal medicineDatabase SearchingResearch IntegrityRandomized Controlled Trials as Topicmedicine.diagnostic_testbiologyAnticholesteremic AgentsStatisticsFatty AcidsRDrugsGeneral MedicineMetaanalysisSerious Mental IllnessLipidsPhase III as TopicMental HealthCholesterolPhysical SciencesMedicineResearch Articlemedicine.medical_specialtyRMScience PolicyLipoproteinsHypercholesterolemiaBempedoic acid hypercholesterolemia lipid profile hsCRPResearch and Analysis MethodsLDL03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineGeneral & Internal MedicinemedicineHumansClinical TrialsStatistical MethodsApolipoproteins BPharmacologyPlasma Proteinsbusiness.industryCholesterolPhase II as TopicStatinsBiology and Life SciencesProteinsOdds ratioCholesterol LDLConfidence intervalPeptide FragmentschemistryClinical Trials Phase III as Topicbiology.proteinUric acidCreatine kinaseLipid profilebusinessDigestive DiseasesMathematicsPLoS Medicine
researchProduct

Advances in haploidentical stem cell transplantation for hematologic malignancies

2016

One of the most important advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the use of alternative donors and cell sources, such as haploidentical transplants (haplo-HSCT) from family donors. Several approaches have been developed to overcome the challenging bidirectional alloreactivity. We discuss these approaches, including ex vivo T-cell-depleted grafts with megadose of CD34(+) cells, not requiring immunosuppression after allogeneic transplantation for graft-versus-host disease (GVHD) prophylaxis, and other strategies using unmanipulated T-cell-replete grafts with intensive immunosuppression or post-transplantation cyclophosphamide to minimize the GVHD. We als…

Cancer ResearchAllogeneic transplantationmedicine.medical_treatmentGraft vs Host DiseaseContext (language use)Hematopoietic stem cell transplantationT-Lymphocytes RegulatoryLymphocyte DepletionDonor Selection03 medical and health sciences0302 clinical medicineReceptors KIRHLA AntigensmedicineHumansCyclophosphamideDonor selectionbusiness.industryHistocompatibility TestingHematopoietic Stem Cell TransplantationImmunosuppressionHematologyAllograftsTransplantationTreatment Outcomesurgical procedures operativeClinical Trials Phase III as TopicOncologyHematologic Neoplasms030220 oncology & carcinogenesisTransplantation HaploidenticalImmunologyStem cellUnrelated DonorsbusinessImmunosuppressive AgentsEx vivo030215 immunologyLeukemia & Lymphoma
researchProduct

Should cirrhosis change our attitude towards treating non-hepatic cancer?

2011

Cirrhosis is a major cause of morbidity and mortality and is the end stage of any chronic liver disease. Cancer, a leading cause of death worldwide, is a growing global health issue. There are limited data in the literature on the incidence, prevalence and management of non-hepatic cancers (NHC) in cirrhotic patients. The aim of this brief review was to underline the main concerns, pitfalls and warnings regarding practice for these patients. Survival of patients with compensated cirrhosis is significantly longer than that of decompensated cirrhosis and patients with NHC and in Child-Pugh class C should not be candidates for cytotoxic chemotherapy. It is important before starting cytotoxic c…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisAntineoplastic AgentsComorbidityChronic liver diseaseGastroenterologyLiver diseaseInternal medicineCause of DeathNeoplasmsmedicineHumansIntensive care medicineSurvival rateCause of deathHepatologybusiness.industryPatient SelectionCancerProfessional Practicemedicine.diseasechemotherapy – cirrhosis – hepatotoxicity – non-hepatic cancerClinical trialSurvival RateClinical Trials Phase III as TopicPortal hypertensionFemaleChemical and Drug Induced Liver InjurybusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Emerging drugs for the treatment of vitiligo.

2020

Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treat…

MAP Kinase Signaling SystemAdministration TopicalVitiligoAdministration OralVitiligoBiologicsBioinformatics030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineClinical Trials Phase II as TopicLocalized vitiligoMedicineHumansJanus Kinase InhibitorsPharmacology (medical)skin and connective tissue diseasesRandomized Controlled Trials as TopicPharmacologytreatmentintegumentary systembusiness.industrymedicine.diseaseCombined Modality TherapyJAK inhibitorchemistryClinical Trials Phase III as Topic030220 oncology & carcinogenesisCytokinesAfamelanotideDermatologic AgentsbusinessJanus kinaseBiologics; JAK inhibitor; treatment; vitiligoExpert opinion on emerging drugs
researchProduct

Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants

2020

AbstractAs a result of the successful completion of their respective phase III studies compared with vitamin K antagonists (VKAs), four direct oral anticoagulants (DOACs) have been approved for the treatment and secondary prevention of venous thromboembolism (VTE). These DOACs—apixaban, dabigatran, edoxaban, and rivaroxaban—have subsequently seen a steady uptake among clinicians since their approval. Despite the suitability of DOACs for a broad range of patients, they are not appropriate in certain situations, whereas in others they require additional considerations such as dose reductions. Subanalyses of phase III trials and studies on specific VTE patient populations have been conducted t…

Male0301 basic medicineComorbidity030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicinePregnancyEdoxabanNeoplasmsSecondary PreventionChildspecial populationsAge FactorsVenous ThromboembolismHematologyMiddle AgedTreatment OutcomePractice Guidelines as TopicFemaleKidney Diseasesmedicine.drugAdultmedicine.medical_specialtyMEDLINEHemorrhagecomorbiditiesdirect oral anticoagulantsDabigatran03 medical and health sciencesmedicineHumansLactationDosingIntensive care medicineAgedDose-Response Relationship Drugbusiness.industryPatient SelectionPregnancy Complications HematologicContraindications DrugAnticoagulantsmedicine.diseaseComorbidityReview articleClinical trial030104 developmental biologyClinical Trials Phase III as TopicchemistrybusinessVenous thromboembolismFactor Xa InhibitorsThrombosis and Haemostasis
researchProduct

Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation.

2007

Telomeres cap chromosomal ends and are shortened throughout a lifetime. Additional telomere erosion has been documented during conventional chemotherapy or hematopoietic stem cell transplantation. Previous studies of stem cell transplantation reported variable amounts of telomere shortening with inconsistent results regarding the persistence of telomere shortening. Here we have prospectively studied telomere length and proliferation kinetics of hematopoietic cells in aggressive non-Hodgkin lymphoma patients who underwent a four-course high-dose chemotherapy protocol combined with triple autologous stem cell transplantation. We observed sustained telomere shortening in hematopoietic cells af…

MaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationAntibodies Monoclonal Murine-DerivedAutologous stem-cell transplantationAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorLymphocytesProspective StudiesCellular SenescenceEtoposideMyelopoiesisLymphoma Non-HodgkinAntibodies MonoclonalHematologyMiddle AgedTelomereCombined Modality TherapyHaematopoiesisVincristineFemaleStem cellRituximabCell DivisionPrednisoloneTransplantation AutologousDrug Administration ScheduleGeneticsmedicineHumansMolecular BiologyCyclophosphamideChemotherapyPeripheral Blood Stem Cell Transplantationbusiness.industryCell BiologyMyeloablative Agonistsmedicine.diseaseHematopoietic Stem CellsTelomereLymphomaTransplantationClinical Trials Phase III as TopicDoxorubicinImmunologyCancer researchbusinessGranulocytesExperimental hematology
researchProduct

Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After A…

2017

Abstract: The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid. We now report CV outcomes during a 5-year follow-up of the patients of the SMILE-4 study. Three hundred eighty-six of the 518 patients completing the study (51.2%) could be tracked after the study end and 265 could be included in the analysis. During the 5.5 (±2.1) years of follow-up, the primary endpoint occurred in 27.8% of patients originall…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier Estimate030204 cardiovascular system & hematologyVentricular Function Leftchemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineRetrospective StudieRisk FactorsClinical endpointOdds Ratiozofenopril030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as Topicleft ventricular dysfunctionMortality ratePharmacology; Cardiology and Cardiovascular MedicineMiddle AgedZofenoprilHospitalizationTreatment OutcomeCardiologyOriginal ArticleDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineHumanmedicine.drugRamiprilmedicine.medical_specialtyLogistic ModelTime FactorSystoleacute myocardial infarctionramiprilDisease-Free SurvivalDrug Administration ScheduleFollow-Up Studie03 medical and health sciencesStatistical significanceInternal medicineEarly Medical InterventionmedicineHumansIntensive care medicineAgedRetrospective StudiesPharmacologyChi-Square DistributionAspirinbusiness.industryRisk FactorAngiotensin-Converting Enzyme InhibitorOdds ratioRecovery of Functionmedicine.diseaseConfidence intervalLogistic ModelschemistryClinical Trials Phase III as Topicbusinessacetyl salicylic acidFollow-Up StudiesJournal of Cardiovascular Pharmacology
researchProduct

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

2020

On behalf of the PETHEMA/GEM Cooperative Group.

MaleOncologyPhysics::Instrumentation and Detectorsmedicine.medical_treatmentKaplan-Meier EstimateHematopoietic stem cell transplantationBiochemistryhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentProspective StudiesComputer Science::Operating SystemsIn Situ Hybridization FluorescenceMultiple myelomaRandomized Controlled Trials as TopicComputer Science::Cryptography and SecurityHazard ratioHematopoietic Stem Cell TransplantationHigh-Throughput Nucleotide SequencingHematologyMiddle AgedFlow CytometryPrognosisCombined Modality TherapyProgression-Free Survivalmedicine.anatomical_structureFemaleClonal HematopoiesisMultiple Myelomamedicine.medical_specialtyImmunologyTransplantation AutologousInternal medicinemedicineHumansClinical significanceProgression-free survivalComputer Science::Distributed Parallel and Cluster ComputingAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryCell Biologymedicine.diseaseTransplantationClinical Trials Phase III as TopicMyelodysplastic SyndromesMutationBone marrowbusinessMonoclonal gammopathy of undetermined significance
researchProduct

Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials

1997

Summary Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. Many treatments have been proposed but considerable uncertainty still remains about their effectiveness. In this review we evaluated the quality, clinical coherence, consistency and results of Randomized Controlled Trials (RCT) of non-surgical treatments for HCC. Methods Thirty-seven RCTs examining the effect of different treatments were retrieved using MEDLINE (November 1978 to December 1995) and a review of reference lists. Selected aspects of the quality of design, conduct and reporting were examined. The odds ratio for the probability of surviving up to one year was calculated according to the …

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentlaw.inventionRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansEmbolizationRandomized Controlled Trials as Topicbusiness.industryArterial EmbolizationLiver NeoplasmsHematologyOdds ratioEmbolization TherapeuticChemotherapy regimenSurgeryClinical trialClinical Trials Phase III as TopicOncologyMeta-analysisImmunotherapybusinessAnnals of Oncology
researchProduct

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

2018

Abstract Context Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). Objective To review emerging evidence in the medical treatment of LUTS. Evidence acquisition An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS. Evidence synthesis The main medical innovation in recent years in overactive bladder (OAB) has been the approval of the first β 3 -adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A, while several other drugs such as antiepil…

Malemedicine.medical_specialtyReceptors VasopressinUrologyUrinary Bladder030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceAdrenergic beta-3 Receptor Agonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineDesmopressin AcetateNocturiaHumansDeamino Arginine VasopressinProspective StudiesBotulinum Toxins Type ADesmopressinRandomized Controlled Trials as TopicRetrospective StudiesUrinary bladderbusiness.industryUrinary Bladder OveractiveAntidiuretic AgentsPhosphodiesterase 5 Inhibitorsmedicine.diseasefemale genital diseases and pregnancy complicationsThiazolesmedicine.anatomical_structureOveractive bladderClinical Trials Phase III as Topic030220 oncology & carcinogenesisModels AnimalAcetanilidesFemaleNocturiamedicine.symptomMirabegronbusinessmedicine.drugEuropean urology focus
researchProduct